Ambagon Therapeutics key facts
- Developer of small-molecule cancer drugs designed to stabilize the direct interaction of oncogenic proteins.
- It has raised $108.0M across 3 recorded rounds; the latest was Early Stage VC ($5.0M) in Jan 2025.
- Notable investors include RA Capital Management, Citadel Enterprise Americas, AbbVie Ventures, Blackwell Partners, Curie.Bio — 13 tracked in total.
- Ambagon Therapeutics has filed 6 Form Ds with the SEC since 2020, most recently Feb 2025 ($5.0M sold to 4 investors).
- Status: Privately Held (backing).
Who backs Ambagon Therapeutics
13+- ·The complete investor list: 13 names
- ·Watch Ambagon Therapeutics: the Monday email on marks, rounds and moves
Ambagon Therapeutics funding rounds
3 roundsHow much has Ambagon Therapeutics raised?
Ambagon Therapeutics has raised $108 million across 3 recorded rounds since 2020. The largest was an $85 million Series A in Jan 2022; the most recent was a $5 million early-stage round in Jan 2025.
Ambagon Therapeutics has filed 6 Form Ds with the SEC since 2020, most recently in Feb 2025 ($5 million sold to 4 investors).
Ambagon Therapeutics investors
13 investors are on record for Ambagon Therapeutics, including RA Capital Management, Citadel Enterprise Americas, AbbVie Ventures and Blackwell Partners. The early-stage round in Jan 2025 drew 4 investors.
About Ambagon Therapeutics
Developer of small-molecule cancer drugs designed to stabilize the direct interaction of oncogenic proteins. The company's drugs selectively augment the endogenous tumor suppression activity of proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conventional approaches, thereby enabling physicians to address other major unmet clinical needs.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Eindhoven, Netherlands
- Founded
- 2019
- Employees
- 17
- Website
- ambagontx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Ambagon Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.